Toward a Vaccine: Opportunities and Challenges to Fight an Antimicrobial-Resistant Pathogen

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Mar 11

PMID 36902092

Authors

Maria Michelina Raso

Vanessa Arato

Gianmarco Gasperini

Francesca Micoli

Affiliations

Soon will be listed here.

Abstract

Shigellosis causes more than 200,000 deaths worldwide and most of this burden falls on Low- and Middle-Income Countries (LMICs), with a particular incidence in children under 5 years of age. In the last decades, has become even more worrisome because of the onset of antimicrobial-resistant strains (AMR). Indeed, the WHO has listed as one of the priority pathogens for the development of new interventions. To date, there are no broadly available vaccines against shigellosis, but several candidates are being evaluated in preclinical and clinical studies, bringing to light very important data and information. With the aim to facilitate the understanding of the state-of-the-art of vaccine development, here we report what is known about epidemiology and pathogenesis with a focus on virulence factors and potential antigens for vaccine development. We discuss immunity after natural infection and immunization. In addition, we highlight the main characteristics of the different technologies that have been applied for the development of a vaccine with broad protection against .

Citing Articles

Shigellosis in an Urban Slum in Kenya: Risk Factors and Antimicrobial Resistance.

Ongadi B, Aziz A, Mbae C, Mwangi M, Kering K, Khan A Open Forum Infect Dis. 2025; 12(2):ofaf026.

PMID: 39963694 PMC: 11832040. DOI: 10.1093/ofid/ofaf026.

Salmonella Typhimurium derived OMV nanoparticle displaying mixed heterologous O-antigens confers immunogenicity and protection against STEC infections in mice.

Bian X, Chen Y, Zhang W, Liu X, Lei M, Yuan H Microb Cell Fact. 2025; 24(1):8.

PMID: 39773741 PMC: 11705740. DOI: 10.1186/s12934-024-02640-6.

Phytochemical Analysis and Antimicrobial Activity of (Gaertn.) Roxb. and Retz. Fruit Extracts Against Gastrointestinal Pathogens: Enhancing Antibiotic Efficacy.

Tiwana G, Cock I, Cheesman M Microorganisms. 2025; 12(12.

PMID: 39770866 PMC: 11728670. DOI: 10.3390/microorganisms12122664.

Shigella sonnei: epidemiology, evolution, pathogenesis, resistance and host interactions.

Scott T, Baker K, Trotter C, Jenkins C, Mostowy S, Hawkey J Nat Rev Microbiol. 2024; .

PMID: 39604656 DOI: 10.1038/s41579-024-01126-x.

Whole genome sequencing and antimicrobial resistance among clinical isolates of Shigella sonnei in Addis Ababa, Ethiopia.

Ayele B, Mihret A, Mekonnen Z, Tessema T, Melaku K, Nassir M PLoS One. 2024; 19(11):e0313310.

PMID: 39531464 PMC: 11556702. DOI: 10.1371/journal.pone.0313310.

References

Micoli F, Rossi O, Conti V, Launay O, Scire A, Aruta M . Antibodies Elicited by the GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension. Front Immunol. 2021; 12:671325. PMC: 8129577. DOI: 10.3389/fimmu.2021.671325. View

Hu B, Morado D, Margolin W, Rohde J, Arizmendi O, Picking W . Visualization of the type III secretion sorting platform of Shigella flexneri. Proc Natl Acad Sci U S A. 2015; 112(4):1047-52. PMC: 4313800. DOI: 10.1073/pnas.1411610112. View

Riddle M, Kaminski R, Williams C, Porter C, Baqar S, Kordis A . Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine. 2011; 29(40):7009-19. DOI: 10.1016/j.vaccine.2011.07.033. View

Taitt C, Leski T, Prouty M, Ford G, Heang V, House B . Tracking Antimicrobial Resistance Determinants in Diarrheal Pathogens: A Cross-Institutional Pilot Study. Int J Mol Sci. 2020; 21(16). PMC: 7460656. DOI: 10.3390/ijms21165928. View

Perepelov A, Shekht M, Liu B, Shevelev S, Ledov V, Senchenkova S . Shigella flexneri O-antigens revisited: final elucidation of the O-acetylation profiles and a survey of the O-antigen structure diversity. FEMS Immunol Med Microbiol. 2012; 66(2):201-10. DOI: 10.1111/j.1574-695X.2012.01000.x. View

Jin Q, Yuan Z, Xu J, Wang Y, Shen Y, Lu W . Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res. 2002; 30(20):4432-41. PMC: 137130. DOI: 10.1093/nar/gkf566. View

Nahm M, Yu J, Weerts H, Wenzel H, Tamilselvi C, Chandrasekaran L . Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Serum Bactericidal Assay. mSphere. 2018; 3(3). PMC: 6001606. DOI: 10.1128/mSphere.00146-18. View

Orr N, Katz D, Atsmon J, Radu P, Yavzori M, Halperin T . Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun. 2005; 73(12):8027-32. PMC: 1307051. DOI: 10.1128/IAI.73.12.8027-8032.2005. View

Herrington D, Van de Verg L, Formal S, Hale T, Tall B, Cryz S . Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine. 1990; 8(4):353-7. DOI: 10.1016/0264-410x(90)90094-3. View

10.

Kapulu M, Nakakana U, Scire A, Sarakinou E, Conti V, Rossi O . Complement-mediated serum bactericidal activity of antibodies elicited by the GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized study. Front Immunol. 2022; 13:971866. PMC: 9531247. DOI: 10.3389/fimmu.2022.971866. View

11.

Raja S, Raman Murali M, Devaraj S . Differential expression of ompC and ompF in multidrug-resistant Shigella dysenteriae and Shigella flexneri by aqueous extract of Aegle marmelos, altering its susceptibility toward beta-lactam antibiotics. Diagn Microbiol Infect Dis. 2008; 61(3):321-8. DOI: 10.1016/j.diagmicrobio.2008.02.006. View

12.

Ross S, BURKE F, RICE E, Washington J, Stevens S . Chloramphenicol (chloromycetin) therapy in Shigella enteritis. J Am Med Assoc. 1950; 143(17):1459-60. DOI: 10.1001/jama.1950.02910520001001. View

13.

Caboni M, Pedron T, Rossi O, Goulding D, Pickard D, Citiulo F . An O antigen capsule modulates bacterial pathogenesis in Shigella sonnei. PLoS Pathog. 2015; 11(3):e1004749. PMC: 4368438. DOI: 10.1371/journal.ppat.1004749. View

14.

Zarei M, Ghahfarokhi M, Fazlara A, Bahrami S . Effect of the bacterial growth phase and coculture conditions on the interaction of Acanthamoeba castellanii with Shigella dysenteriae, Shigella flexneri, and Shigella sonnei. J Basic Microbiol. 2019; 59(7):735-743. DOI: 10.1002/jobm.201900075. View

15.

Perwaiz S, Tuchweber B, Mignault D, Gilat T, Yousef I . Determination of bile acids in biological fluids by liquid chromatography-electrospray tandem mass spectrometry. J Lipid Res. 2001; 42(1):114-9. View

16.

Okuda J, Toyotome T, Kataoka N, Ohno M, Abe H, Shimura Y . Shigella effector IpaH9.8 binds to a splicing factor U2AF(35) to modulate host immune responses. Biochem Biophys Res Commun. 2005; 333(2):531-9. DOI: 10.1016/j.bbrc.2005.05.145. View

17.

Martin P, Alaimo C . The Ongoing Journey of a Bioconjugate Vaccine. Vaccines (Basel). 2022; 10(2). PMC: 8878964. DOI: 10.3390/vaccines10020212. View

18.

Puzari M, Sharma M, Chetia P . Emergence of antibiotic resistant Shigella species: A matter of concern. J Infect Public Health. 2017; 11(4):451-454. DOI: 10.1016/j.jiph.2017.09.025. View

19.

Jamal M, Chaudhry W, Hussain T, DAS C, Andleeb S . Characterization of new Myoviridae bacteriophage WZ1 against multi-drug resistant (MDR) Shigella dysenteriae. J Basic Microbiol. 2015; 55(4):420-31. DOI: 10.1002/jobm.201400688. View

20.

Tribble D . Resistant pathogens as causes of traveller's diarrhea globally and impact(s) on treatment failure and recommendations. J Travel Med. 2017; 24(suppl_1):S6-S12. PMC: 5731445. DOI: 10.1093/jtm/taw090. View